Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment

Detalles Bibliográficos
Autores principales: Manouchehri, Navid, Stüve, Olaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970673/
https://www.ncbi.nlm.nih.gov/pubmed/33796142
http://dx.doi.org/10.1177/1756286421990500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970673/
https://www.ncbi.nlm.nih.gov/pubmed/33796142
http://dx.doi.org/10.1177/1756286421990500

Ejemplares similares